HanchorBio Reaches Clinical Milestone for HCB101 as US FDA Allows Continued Treatment for Phase 1 Patient Experiencing Clinical Benefit

HanchorBio announced that HCB101 is the first known U.S. Expanded Access case for a SIRPα Fc fusion protein, allowing a patient to continue treatment beyond the parent clinical study. The development provides an early positive regulatory-access milestone for the clinical-stage biotech, but the excerpt includes no efficacy, safety, financial, or commercial data.